Abgenix Inc. - ABGX- Profile

Abgenix, Inc.. The Group's principal activities are to develop and market fully human monoclonal antibody therapies for cancer inflammation and metaolic diseases. The Group's technology and integrated product development platform enable rapid generation and selection of product candidates for disease targets appropriate for antibody therapy. It leverages the human antibody technology to build a large and diversified product portfolio. It develops its own proprietary products internally and establishes licensing arrangements with multiple biopharmaceutical collaborators. The Group has two products in development: ABX-EGF and ABX-PTH in clinical trials. In addition, the Group has four customer-developed antibodies generated with XenoMouse technology in clinical trials from collaborations at Amgen and Pfizer. Discovers, develops & manufactures human therapeutic antibodies for the treatment cancer, inflammation and metabolic disease